Intratumoral injections of CTLA-4 inhibitors have been clinically effective to date, with demonstrated efficacy and safety in phase I clinical trials for the treatment of advanced melanoma, and also showed an enhanced systemic anti-tumor immune response induced by local injections (77). This evidence concerns the gene CTLA4 and neoplasm.